GlassScriptPhysician profile
Becky J Emerson
NPI 1184669384
$2,496.42
in general payments reported to CMS, 2019-2025
43 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $254 · 2023: $1,227 · 2024: $593 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971 · Education: $63.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.94 |
| Education | $63.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $258.14 | 2021-2024 | Ingrezza, Ongentys |
| Abbvie INC. | $251.84 | 2021-2025 | |
| Genentech, INC. | $137.82 | 2023-2024 | Ocrevus |
| Janssen Pharmaceuticals, INC | $135.03 | 2022 | |
| Sk Life Science, INC. | $115.90 | 2023-2024 | Xcopri |
| Amylyx Pharmaceuticals, INC. | $114.93 | 2023 | Relyvrio |
| Baxter Healthcare | $114.51 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Eisai INC. | $110.39 | 2023-2025 | |
| Genentech USA, INC. | $99.54 | 2021-2024 | Ocrevus |
| Biogen, INC. | $97.56 | 2023-2025 | Vumerity, Spinraza, Qalsody |
| Tg Therapeutics, INC. | $88.52 | 2023 | |
| Celgene Corporation | $79.39 | 2022-2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $63.67 | 2023-2024 | Hyqvia |
| Argenx US, INC. | $55.09 | 2023-2024 | Vyvgart |
| Csl Behring | $54.73 | 2023 | Hizentra |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Becky Emerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.